




RealRate

PHARMACEUTICAL 2018

Supernus Pharmaceuticals INC
Rank 104 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Supernus Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 26% points.

The company's Economic Capital Ratio, given in the ranking table, is 316%, being 64% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	228,451
Cost of Goods Sold	0
Intangible Assets	36,019
Liabilities, Current	123,000
Liabilities, Non-Current	10,577
Other Assets	154,870
Other Compr. Net Income	-613
Other Expenses	58,549
Other Liabilities	23,407
Other Net Income	1,077
Other Revenues	302,238
Property and Equipment	5,124
Research and Development	49,577
Selling, General and Administrative Expense	137,905

Output Variable	Value in 1000 USD
Assets	424,464
Liabilities	156,984
Expenses	246,031
Revenues	302,238
Stockholders Equity	267,480
Net Income	57,284
Comprehensive Net Income	56,978
BaseVar	565,704
ECR before Limited Liability	220%
Economic Capital Ratio	316%